News
NTRB
4.080
-4.45%
-0.190
Weekly Report: what happened at NTRB last week (1209-1213)?
Weekly Report · 5d ago
Weekly Report: what happened at NTRB last week (1202-1206)?
Weekly Report · 12/09 12:08
Nutriband Inc. Reports Financial Results for the Quarter Ended October 31, 2024
Press release · 12/04 20:33
Nutriband Inc. Reports Record Third Quarter Revenue and Advances AVERSA™ Fentanyl Development Plans
Barchart · 12/04 18:24
Nutriband Q3 EPS $(0.12) Up From $(0.22) YoY, Sales $645.80K Up From $427.84K YoY
Benzinga · 12/04 14:07
Nutriband reports record revenue for Q3, progress to NDA for AVERSA
TipRanks · 12/04 14:06
Press Release: Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Dow Jones · 12/04 14:00
Weekly Report: what happened at NTRB last week (1125-1129)?
Weekly Report · 12/02 12:09
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/29 21:06
NUTRIBAND RECEIVES HONG KONG PATENT NOTICE OF PUBLICATION FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
Reuters · 11/27 12:03
Weekly Report: what happened at NTRB last week (1118-1122)?
Weekly Report · 11/25 11:57
Weekly Report: what happened at NTRB last week (1111-1115)?
Weekly Report · 11/18 11:54
Weekly Report: what happened at NTRB last week (1104-1108)?
Weekly Report · 11/11 12:12
Weekly Report: what happened at NTRB last week (1028-1101)?
Weekly Report · 11/04 12:07
Nutriband Secures Chinese Patent for AVERSA™ Technology
TipRanks · 10/31 16:56
Nutriband issued CNIPA patent for abuse, misuse deterrent transdermal system
TipRanks · 10/31 13:00
Weekly Report: what happened at NTRB last week (1021-1025)?
Weekly Report · 10/28 11:57
Weekly Report: what happened at NTRB last week (1014-1018)?
Weekly Report · 10/21 11:52
Nutriband receives Costa Rica MoH approval for Mosquito Repellent Patch
TipRanks · 10/17 11:18
Weekly Report: what happened at NTRB last week (1007-1011)?
Weekly Report · 10/14 12:29
More
Webull provides a variety of real-time NTRB stock news. You can receive the latest news about Nutriband Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.